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Abstract
Molecular apocrine is a subtype of estrogen receptor–negative (ER−) breast cancer, which is characterized by a
steroid-response gene signature that includes androgen receptor, FOXA1, and a high frequency of ErbB2 over-
expression. In this study, we demonstrate that there is a strong association between the overexpression of FOXA1
and ErbB2 in ER− breast tumors. This has led us to identify a cross-regulation network between FOXA1 and ErbB2
signaling in ER− breast cancer. We present two mechanisms to explain the association between FOXA1 and
ErbB2 overexpression in molecular apocrine cells. In one process, ErbB2 signaling genes CREB1 and c-Fos regu-
late FOXA1 transcription, and in another process, AP2α regulates the expression of both FOXA1 and ErbB2. More-
over, we demonstrate that FOXA1, in turn, regulates the transcription of ErbB2 signaling genes. This includes a
core gene signature that is shared across two molecular apocrine cell lines. Importantly, the most upregulated
(RELB) and downregulated (PAK1) genes in this signature are direct FOXA1 targets. Our data suggest that FOXA1
acts as a dual-function transcription factor and the repressive function of FOXA1 on RELB can be explained by the
recruitment of its binding partner corepressor TLE3. It is notable that a group of FOXA1-regulated genes vary
across molecular apocrine cell lines leading to the differences in the functional effects of FOXA1 on extracellular
signal–regulated kinase phosphorylation and cell viability between these lines. This study demonstrates that there
is a cross-regulation network between FOXA1 and ErbB2 signaling that connects FOXA1 to some of the key sig-
naling pathways in ER− breast cancer.
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Introduction
Estrogen receptor–negative (ER−) breast cancer is a heterogeneous
disease that constitutes around 30% of all cases [1]. To develop effec-
tive targeted therapies for ER− breast cancer, there is need to better
understand the biology of this disease. ER− breast cancer can be di-
vided into molecular apocrine and basal subtypes based on expression
microarray profiling [2]. Molecular apocrine subtype is characterized
by a steroid-response gene signature that includes androgen receptor
(AR), FOXA1, TFF3, and a high frequency of ErbB2 overexpression
(ErbB2+) [2–4]. Recent studies have shown that AR expression is
observed in approximately 50% of ER− breast tumors and more than
50% of these cases also have ErbB2 overexpression [5–7].
There is a growing body of evidence to support a significant role
for the AR and ErbB2 signaling pathways in molecular apocrine
breast cancer. Notably, there is a functional cross talk between the
AR and ErbB2 signaling in molecular apocrine cells, which modulates
cell proliferation and expression of steroid-response genes [8]. More-
over, we have recently identified a positive feedback loop between
the AR signaling and extracellular signal–regulated kinase (ERK) path-
ways in molecular apocrine breast cancer [9]. In this feedback loop,
AR regulates ERK phosphorylation through the mediation of ErbB2
and, in turn, ERK-CREB1 signaling regulates the transcription of
AR inmolecular apocrine cells [9]. Furthermore, it has been shown that
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AR mediates ligand-dependent activation of Wnt and ErbB2 signaling
pathways through direct transcriptional induction of WNT7B and
ErbB3 [10]. Importantly, AR signaling is a potential therapeutic target
in ER−/AR+ breast cancer [10–13].
Another notable gene in the molecular apocrine signature is the
transcription factor FOXA1 [2–4]. FOXA1 has emerged as a critical
modulator of ER and AR function with a significant role in breast
and prostate cancers [14–18]. In addition, recent studies suggest that
FOXA1 has a complex regulatory function with the ability to both
facilitate and restrict key transcription factors such as AR [15,19].
However, there are limited data available regarding the function of
FOXA1 in ER− breast cancer. Moreover, although GATA3 and ERα
are known transcriptional activators of FOXA1 in ER+ breast cancer
[20,21], the regulation of FOXA1 in ER− tumors is poorly understood.
We have previously demonstrated that, in a subset of ER−/AR+
breast cancer cells, heregulin, which activates ErbB2 and ErbB3,
induces FOXA1 expression [8]. Furthermore, gene expression analy-
sis has revealed that FOXA1 is expressed in approximately 70% of
ErbB2+ breast tumors [22]. These findings suggest that ErbB2
signaling may have a role in the regulation of FOXA1; however,
the mechanism involved in this process is yet to be identified.
In this study, we investigate a cross-regulation between FOXA1
and ErbB2 signaling in molecular apocrine breast cancer. We dem-
onstrate that ErbB2 signaling activates FOXA1 mediated through its
downstream transcription factors and FOXA1, in turn, regulates a
distinct group of ErbB2 signaling genes.
Materials and Methods
Tissue Microarray Cohort and Immunohistochemistry
Three sets of breast cancer tissue microarray (TMA) slides were
obtained from Pantomics (http://www.pantomics.com/tissue-arrays/
Systems.htm#Breast_disease_tissue_arrays; BRC1501-3, Richmond,
CA) as they were published before [23]. The TMA slides constituted
of a total of 79 ER− breast tumors with known ErbB2 status. Immuno-
histochemistry (IHC) staining was performed using EnVision+ System-
HRP (DakoCytomation, Sydney, Australia). Antigen retrieval was carried
out using Target Retrieval Solution (DakoCytomation). Primary anti-
body incubation was performed with FOXA1 rabbit polyclonal antibody
(ab23738) from Abcam (Cambridge, United Kingdom) at 1:200 dilu-
tion [24,25]. TMA cores were examined at 60× magnification using
a light microscope (Nikon Instruments, Inc, Tokyo, Japan). A total of
1000 nuclei per each TMA slide were assessed, and the average score
for two replicate slides was used for the analysis.
Scoring for FOXA1 was carried out based on a previously described
semiquantitative scoring system [26]. On the basis of this system, per-
centage (P: score of 1 for each 10% positive tumor nuclei such as 10 =
91%-100%) and intensity (I : 1+ to 3+) of nuclear expression were
multiplied to generate a numerical score (S = P × I ), which could
vary between 0 and 30 [26]. In our study, FOXA1 overexpression
(FOXA1+) was defined as S > 15 (e.g., intense nuclear staining [3+]
in >50% of cells). Using the median score as a cutoff has been previ-
ously used to assess protein overexpression in immunohistochemistry
studies [27,28].
Cell Culture
Breast cancer cell lines MDA-MB-453, HCC-1954, and MCF-7
were obtained from the American Type Culture Collection (Manassas,
VA). All tissue culture media were obtained from Invitrogen (Melbourne,
Australia). MDA-MB-453 and HCC-1954 cell lines were cultured
in L15 medium, 10% fetal bovine serum, and RPMI 1640 medium,
respectively. The MCF-7 cell line was cultured in Dulbecco modi-
fied Eagle medium/F12 medium and 10% fetal bovine serum. Treat-
ment with MEK inhibitor, CI-1040 (PD184352; Selleck Chemicals,
Houston, TX) at 10 μM concentration, was carried out for 24 hours
in full media.
Western Blot Analysis
FOXA1 rabbit polyclonal antibody was obtained from Abcam. Rab-
bit monoclonal ERK1/2 antibody and rabbit monoclonal phospho-
ERK1/2 (Thr202/Tyr204) were obtained from Cell Signaling
(Danvers, MA). Western blots were carried out at 1:1000 dilution of
each primary antibody using 10 and 20 μg of cell lysates for the total
and phospho-proteins, respectively. Protein concentrations from the
cell isolates were measured using the BCA Protein Assay Kit (Thermo
Scientific, Melbourne, Australia). Rabbit polyclonal α-tubulin antibody
(Abcam) was used as the loading control. Analysis of band densities was
performed using Bio-Profil Densitometer Software (Vilber Lourmat,
Eberhardzel, Germany). All fold changes in band densities were mea-
sured relative to the control groups. Western blots were done in two
biologic replicates, and the average fold change was shown for each set
of experiments.
Real-time Polymerase Chain Reaction Analysis
Total RNA extraction was performed as described before [29].
Real-time polymerase chain reaction (RT-PCR) to assess the expres-
sion levels of FOXA1 (assay ID: Hs00270129_m1), RELB (assay ID:
Hs00232399_m1), and TLE3 (assay ID: Hs00183222_m1) was car-
ried out using TaqMan Gene Expression Assays (Applied Biosystems,
Melbourne, Australia) as instructed by the manufacturer. Housekeep-
ing gene RPLP0 (Applied Biosystems) was used as a control. Relative
gene expression = gene expression in the knockdown group / average
gene expression in the control group. All experiments were performed
in three biologic replicates.
FOXA1 Knockdown in Cell Lines
FOXA1 knockdown (KD) was carried out as described before [30]
in MDA-MB-453 and HCC-1954 cells using the following small
interfering RNA (siRNA) oligos (duplex; Sigma-Aldrich, Sydney,
Australia): D1, 5′CACACAAACCAAACCGUCA; D2, 5′UGA-
CGGUUUGGUUUGUGUG. TLE3 KD was carried out using
the following two sets of siRNA oligos (duplex; Sigma-Aldrich):
set 1: D1, 5′GUCAUCUACUAAACAAGAA; D2, 5′UUCUU-
GUUUAGUAGAUGAC; and set 2: D1, 5′GUCAUCUACUAAA-
CAAGAA; D2, 5′UUCUUGUUUAGUAGAUGAC. Transfection
of siRNA oligos using Lipofectamine RNAiMAX (Invitrogen) was
carried out with a reverse transfection method as instructed by the
manufacturer. The final siRNA duplex concentration was 20 nM
for the KD experiments. Cells transfected with siRNA Universal
Negative Control No. 1 (Sigma-Aldrich) were used as controls.
In all experiments, the effects of KDs were assessed 72 hours after
the siRNA transfections.
Epidermal Growth Factor Pathway Arrays
TaqMan Human Epidermal Growth Factor (EGF) Pathway
Arrays constituting of 96 genes were obtained from Applied Bio-
systems (Part No: 4418774, the layout of this array is available under
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the following link: http://www3.appliedbiosystems.com/cms/groups/
portal/documents/web_content/dev_043045.gif). Transfections with
FOXA1-siRNA oligos and control-siRNA were carried out in MDA-
MB-453 andHCC-1954 cell lines as described previously. Seventy-two
hours after transfections, total RNA was extracted for RT-PCR analysis.
The efficiency of FOXA1-KD was validated using RT-PCR as de-
scribed previously. A total of eight arrays were applied for two biologic
replicate experiments with each of the FOXA1-siRNA and control-
siRNA oligos in MDA-MB-453 and HCC-1954 cell lines (four arrays
per cell line).
After RT-PCR experiments using human EGF pathways arrays,
cycle threshold (CT) values in each array plate were normalized to
the mean CT values of four housekeeping genes on the plates (18S,
GAPDH, HPRT1, and GUSB) to obtain ΔCT values for each gene.
Next, the average ΔCT values for the control-siRNA plates in each cell
line were deducted from the ΔCT values of the corresponding genes
on FOXA1-siRNA plates to obtain ΔΔCT values. Finally, relative
gene expressions were calculated using 2−ΔΔCT formula as described
before [31].
Luciferase Reporter Assays
Full-length complementary DNA (cDNA) clones for CREB1,
c-Jun, c-Fos, and AP2α were obtained from Open Biosystems
(Thermo Scientific). Full-length cDNA clone for Elk1 was ob-
tained from GeneCopoeia (Rockville, MD). The clones were vali-
dated by restriction digestion/sequencing and then subcloned into
a pcDNA3.1 vector (Invitrogen) to generate expression constructs.
The sequence of 1.5-kb promoter region of FOXA1 was obtained
using Ensembl Genome Browser (http://www.ensembl.org/index.
html) and PCR generated using the following primer set: forward,
GCGCGGTACCCGCAGTGCAGATGCGTTCCC; reverse,
GCGCGAGCTCACCTCCTGCGTGTCTGCGTAGT. Sub-
sequently, FOXA1 promoter was cloned into a pGL3 luciferase
reporter vector (Promega, Sydney, Australia) and validated by restric-
tion digestion/sequencing.
To carry out the reporter assays, MCF-7 cells were cotransfected
with the FOXA1 reporter vector and each of the transcription fac-
tors using ExGen 500 reagent (Fermentas Life Sciences, St Leon-
Rot, Germany). The Renilla pRL-TK vector (Promega) was used as
an internal control reporter. Cotransfection with FOXA1 reporter
vector and an empty pcDNA vector was used as a control. Forty-
eight hours after the transfections, reporter activities were measured
using Dual-Glo Luciferase Assay System (Promega) in an Orion II
Microplate Luminometer (Berthold Detection Systems, Pforzheim,
Germany). The response ratios for transcription factors and con-
trol were measured relative to the internal control reporter (relative
response ratio). All reporter assays were carried out in four bio-
logic replicates.
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation (ChIP) assays were performed in
MDA-MB-453 cell line using ChIP Assay Kit (USB Corporation,
Cleveland, OH) as instructed by the manufacturer [32]. ChIP-grade
rabbit monoclonal CREB1 (ChIPAb+ CREB Kit; Millipore,
Melbourne, Australia), rabbit polyclonal AP2α (Abcam), rabbit poly-
clonal c-Fos (Abcam), rabbit polyclonal FOXA1 (Abcam), and rabbit
polyclonal TLE3 (Proteintech, Chicago, IL) antibodies were applied
at 4 μg per assay.
Two primer sets for each of the FOXA1, RELB, and PAK1 pro-
moters were used for the end point RT-PCR amplification using
SYBR green method (Applied Biosystems). FOXA1 promoter primers
included the following: forward primer set 1, TCACTTGGCTC-
GGCTGACT (start: −960); reverse primer set 1, AGCCCCAC-
TTTTGCTTCGT (start: −902); forward primer set 2, CTCCCC-
ATTTCCCTCTTTCC (start site: −565); and reverse primer set 2,
TGTTTGCAAAGCAGTGTAATTGG (start site: −505). RELB pro-
moter primers included the following: forward primer set 1,
CGCCCGGCCTCCAA (start site: −714); reverse primer set 1, GAC-
CAGCGCCTGGAACAC (start site: −664); forward primer set 2,
GGTAAGGCGTGATGGCTCTAAG (start site: −381); and reverse
primer set 2, CGTCGCTGCCCATTGC (start site: −319). PAK1
promoter primers included the following: forward primer set 1,
CTCTTGAGCCCTGGAGTTTGA (start site: −877); reverse primer
set 1, CAGGCTGGAGTGCAGTGGTA (start site: −815); forward
primer set 2, TGAATGGGTGTGGCTGTGTT (start site: −567);
and reverse primer set 2, TGGACTGTATCAAGGGTCAGGAA
(start site: −494). Amplification of input chromatin before immuno-
precipitation at a dilution of 1:50 was used as a positive control. ChIP
assays using nonspecific antibody (rabbit IgG) served as a negative
control. The assays were carried out in three replicates and copy
number changes were calculated as −Log2 value for each experi-
mental set.
Cell Viability Assay
FOXA1-KD in MDA-MB-453 and HCC-1954 cells was carried
out using reverse transfection as described previously. A total of
10,000 cells transfected with either FOXA1-siRNA or control-siRNA
were seeded per each well of a 96-well plate. Seventy-two hours after
transfections, cell viability was assessed using Vybrant MTT Prolifer-
ation Assay Kit (Invitrogen) as instructed by the manufacturer. MTT
assays were performed in eight biologic replicates, and absorbance at
570 nm was measured using a plate reader.
Bioinformatics and Statistical Analysis
Analysis of gene expression correlations. Expressions of FOXA1,
AP2α, and ErbB2 in a total of 30 ER− breast cancer cell lines were
extracted from the microarray data published by Neve et al. [33].
Expression data were normalized to the median expression of each
gene across the cohort of ER− cell lines. Correlation coefficients be-
tween the normalized expression values of FOXA1 with those of
ErbB2 and AP2α were obtained using the Pearson method.
Promoter analysis. Sequences of the 1-kb promoter region of
FOXA1, RELB, and PAK1 genes were obtained using Ensembl
Genome Browser (http://www.ensembl.org/index.html). Identification
of putative binding sites in the promoter regions was carried out using
PATCH public 1.0 software (http://www.gene-regulation.com/cgi-
bin/pub/programs/patch/bin/patch.cgi).
Bioinformatics and statistical analysis. Heat map was generated
using Spotfire DecisionSite for Functional Genomics (TIBCO,
Somerville, MA). Biostatistical analysis was carried out using IBM
SPSS Statistics 20 (Armonk, NY). The Mann-Whitney U test was
applied for the comparison of nonparametric data. All error bars
depict ±2 SEM.
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Results
FOXA1 Is Frequently Overexpressed in ErbB2+/
ER− Breast Tumors
To assess the association between FOXA1 and ErbB2 overexpres-
sion in ER− breast cancer, we carried IHC staining for FOXA1 pro-
tein expression in a TMA cohort of 79 ER− tumors with known
ErbB2 status as described in the Materials and Methods. This cohort
constituted of a total of 36 ErbB2+ tumors defined as 3+ IHC stain-
ing for ErbB2 and 43 ErbB2− tumors. After IHC scoring of FOXA1
staining, we compared the percentage of FOXA1+ tumors, as de-
fined by S > 15, between ErbB2+ and ErbB2− groups. Notably,
we observed that ErbB2+ tumors had approximately 2.5-fold higher
frequency of FOXA1 overexpression at 72% ± 7% compared with
that of ErbB2− tumors at 30% ± 7% (P < .01; Figure 1, A-C ). In
addition, we analyzed the data using a cutoff of S > 24 as applied
by Mehta et al. [34]. This approach also demonstrated a higher level
of FOXA1 expression in ErbB2+ compared with ErbB2− tumors
(Figure W1).
We next tested whether FOXA1 overexpression could be predicted
based on ErbB2 status using receiver operating characteristic analysis.
This method demonstrated an area under the curve (AUC) of 0.71
for predicting FOXA1+ tumors based on ErbB2 status, indicating
that ErbB2 status can classify FOXA1 expression pattern in ER−
breast tumors (P < .01; Figure 1D). Altogether, these findings sug-
gest that FOXA1 overexpression is associated with ErbB2+ status in
ER− breast tumors.
FOXA1 Expression Correlates with ErbB2 and AP2α
Transcript Levels in ER− Cell Lines
We further assessed the association between FOXA1 and ErbB2
expression patterns using the expression microarray data available
from a cohort of thirty ER− breast cancer cell lines [33]. In addition,
we examined a possible association between the expression of
FOXA1 and AP2α using this data set. AP2α is a transcription factor
with an established role in the regulation of ErbB2 expression and
is also a top-ranking gene in the steroid-response gene signature
[3,35–40]. Therefore, a possible association between FOXA1 and
AP2α expression would have potential biologic significance in
ErbB2+/ER− breast cancer.
The expression data for FOXA1, ErbB2 and AP2α were extracted and
normalized as described in the Materials andMethods (Table W1). We
next measured Pearson correlation coefficients (CCs) between the
expression of FOXA1 and that of ErbB2 and AP2α. Notably, FOXA1
expression had significant correlations with the expression of both
ErbB2 (CC = 0.56, P < .01; Figure 1E) and AP2α (CC = 0.6, P < .01;
Figure 1F). These data further confirm a robust association between
FOXA1 and ErbB2 expression patterns in ER− breast cancer. In addi-
tion, AP2α and ErbB2 expressions have a similar level of correlation
with that of FOXA1 in ER− cell lines.
ERK Regulates FOXA1 Expression
We next investigated the underlying mechanism for the observed
overexpression of FOXA1 in ErbB2+/ER− breast tumors. A possible
mechanism for this association is the regulation of FOXA1 transcrip-
tion by the ErbB2 signaling pathway. To assess this possibility, we
first examined the effect of ERK, an important downstream mediator
of ErbB2 signaling, on FOXA1 expression using MEK inhibitor
CI-1040 [9]. MDA-MB-453 and HCC-1954 cell lines were treated
with CI-1040 at 10 μM concentration for 24 hours, and vehicle
(DMSO)-treated cells were used as controls. FOXA1 expression was
then assessed using RT-PCR and Western blot analysis. We observed
that MEK inhibition reduced the level of FOXA1 transcript and pro-
tein levels by approximately 35% (Figure 2, A and B). These findings
suggest that ERK signaling regulates FOXA1 expression in molecular
apocrine cells.
FOXA1 Is a Target of CREB1, AP2α, and c-Fos
Transcription Factors
To further identify a mechanism for our observations, we studied
whether FOXA1 is regulated by some of the key transcription factors
in the ErbB2-ERK signaling pathway. In this respect, we examined
CREB1, Elk1, c-Jun, and c-Fos, which are well-characterized down-
stream mediators of ErbB2-ERK signaling [41–46]. In addition, we
investigated a potential role for AP2α in the regulation of FOXA1
because we observed a significant correlation between AP2α and
FOXA1 expression (Figure 1F ) as well as the fact that AP2α is a crit-
ical regulator of ErbB2 transcription [35–40].
Examination of 1-kb FOXA1 promoter region identified several
putative binding sites for the previously mentioned transcription fac-
tors (Figure 2C ). We subsequently used luciferase reporter assays to
examine the effects of these predicted transcription factors on the reg-
ulation of FOXA1 promoter. Owing to a high degree of transfectabil-
ity, MCF-7 cells were used for the reporter assay experiments [9,32].
MCF-7 cells were cotransfected with the FOXA1 reporter vector and
each of the CREB1, c-Jun, c-Fos, AP2α, and Elk1 expression con-
structs. Cotransfection with the FOXA1 reporter vector and an empty
pcDNA vector was used as a control. Forty-eight hours after the trans-
fections, reporter activities were measured, and relative response ratios
were calculated as described in Materials and Methods. We observed
a marked increase in FOXA1 reporter activity with CREB1 by ap-
proximately 12-fold (P < .01; Figure 2D). In addition, there was an
approximately three-fold increase in FOXA1 reporter activity with
AP2α and c-Fos constructs (P < .01; Figure 2D). However, c-Jun
and Elk-1 did not activate the FOXA1 promoter (Figure 2D).
To assess the binding of CREB1, AP2α, and c-Fos to FOXA1 pro-
moter, we next carried out ChIP assays in MDA-MB-453 cell line.
Two sets of primers for FOXA1 promoter in proximity to the pre-
dicted binding sites were used for the end point RT-PCR amplifica-
tion (Figure 2C ). Amplification of input chromatin at a dilution of
1:50 and ChIP using nonspecific antibody (rabbit IgG) were applied
as positive and negative controls, respectively. Copy number changes
were calculated as −Log2 value for each experimental set (Figure 2,
E and F ). Importantly, we observed a significant enrichment for
FOXA1 promoter region with each of the CREB1, AP2α, and c-Fos
antibodies using both primer sets (P < .01; Figure 2, E and F ). Alto-
gether, these data demonstrate that FOXA1 is a target gene of CREB1,
AP2α, and c-Fos transcription factors.
FOXA1 Regulates a Gene Signature in the ErbB2
Signaling Pathway
We next explored whether FOXA1 has a role in transcriptional
regulation of the EGFR-ErbB2 signaling pathway. To investigate this
possibility, we assessed the effect of FOXA1-KD on the expression of
EGFR-ErbB2 signaling genes in MDA-MB-453 and HCC-1954 cell
lines using Human EGF Pathway Arrays as described in Materials
and Methods. FOXA1-KD was carried out using a siRNA duplex,
and the efficiency of KD was evaluated by Western blot analysis
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Figure 1. The association between FOXA1 and ErbB2 expression in ER-negative breast tumors and cell lines. FOXA1 IHC in a breast
tumor with ErbB2 overexpression (ErbB2+; A) and in an ErbB2− breast tumor (B). Magnifications, ×10. (C) Percentage of FOXA1+
staining using IHC in ErbB2+/ER− and ErbB2−/ER− breast tumors. *P < .01 is for ErbB2+ versus ErbB2− groups. Error bars, ±2 SEM.
(D) Receiver operating characteristic analysis to test ErbB2 status as a predictor for FOXA1 overexpression (FOXA1+) in ER− breast tumors.
Dashed line is a diagonal reference line. (E) Scatterplot to demonstrate the correlation between the relative expression of FOXA1 and ErbB2
in ER− cell lines. Regression fitted line using the quadratic method is depicted. (F) Scatterplot to demonstrate the correlation between
relative expression of FOXA1 and AP2α as described in E.
Neoplasia Vol. 14, No. 4, 2012 Cross-regulation between FOXA1 and ErbB2 Naderi et al. 287
Figure 2. The regulation of FOXA1 expression by ErbB2− ERK signaling. (A) Relative expression of FOXA1 using RT-PCR in HCC-1954
cell line after treatment with CI-1040 (MEK Inh.) at 10 μM concentration for 24 hours. Expression is relative to that of vehicle-treated cells
(CTL). *P < .01 is for CI-1040 versus control. (B) FOXA1 protein levels using Western blot analysis in MDA-MB-453 cell line after treat-
ment with CI-1040 as described in A. (C) Putative transcription factor binding sites for CREB1, c-Jun, c-Fos, AP2α, and Elk1 in 1-kb
promoter region of FOXA1. P1 (primer set 1) and P2 (primer set 2) are regions of amplification for ChIP assays. (D) Luciferase reporter
assay. The transcriptional activation of FOXA1 promoter by CREB1, c-Jun, c-Fos, AP2α, and Elk1 expression constructs was assessed
using dual-luciferase assays in MCF-7 cells, and relative response ratios are reported. Cotransfection with the FOXA1 reporter vector and
an empty pcDNA vector was used as a control. *Compared with the control group. (E) ChIP assay using CREB1, AP2α, and c-Fos anti-
bodies and primer set 1 in MDA-MB-453 cell line. The results of end point RT-PCR amplification for ChIP assay are demonstrated with
primer set 1 for FOXA1 promoter. Input indicates input chromatin at a dilution of 1:50; Neg. CT, nonspecific antibody. The relative copy
number changes to control are shown as −Log2 values. *P < .01 is for each antibody versus Neg. CT. (F) ChIP assay using CREB1,
AP2α, and c-Fos antibodies and primer set 2 as described in E. All error bars, ±2 SEM.
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and RT-PCR. We observed at least 80% reduction of FOXA1 tran-
script and protein levels after FOXA1-KD (Figure 3, A and B). It is
notable that RT-PCR validations of FOXA1-KD were carried out in
all replicate experiments applied for Human EGF Pathway Arrays
(Figure 3B).
We subsequently carried out RT-PCR using Human EGF Path-
way Arrays and analyzed the expression data as described in Mate-
rials and Methods. We identified genes with more than two-fold
change in expression between FOXA1-KD and control experi-
ments. Importantly, there was a core gene signature consisting of
ten genes that showed more than two-fold change in expression af-
ter FOXA1-KD in both MDA-MB-453 and HCC-1954 cell lines
(Figure 3C ). This FOXA1-regulated gene signature included six
upregulated and four downregulated genes (Figure 3C ). The up-
regulated genes were RELB (8.5-fold), c-Fos (3.1-fold), MAP3K1
(3-fold), PRKCE (2.9-fold), R-Ras (2.8-fold), and CDH1 (2.4-fold),
with mean fold increase in their expression levels across two cells
lines ranging from 2.4- to 8.5-fold (Figure 3C ). The downregulated
genes included PAK1 (0.29), PRKCB (0.33-fold), VAV3 (0.33-
fold), and CSK (0.42-fold), with mean fold reduction in their
expression levels across two cells ranging from 0.29- to 0.42-fold
(Figure 3C ).
Moreover, we identified a separate group of genes, with more than
a two-fold change in expression after FOXA1-KD, which were dif-
ferent between MDA-MB-453 and HCC-1954 cell lines (Figure 4,
A and B). This differentially regulated gene list in MDA-MB-453 cell
line included BRAF, GRB2, IKBKB, MAPK9, and MAP2K7 that
were downregulated by 0.27- to 0.49-fold (Figure 4A). In HCC-
1954 cell line, CAV2, CBL, and MYC were upregulated by 2.6- to
3.7-fold and DIRAS3, EGF, and RHOB were downregulated by
0.12- to 0.33-fold (Figure 4B).
These findings suggest that FOXA1 regulates the transcription of a
gene signature in the ErbB2 signaling pathway. In addition, FOXA1
has both positive and negative regulatory effects on ErbB2 signaling
genes as evidenced by down-regulation and up-regulation of these
genes after FOXA1-KD, respectively.
Differences in FOXA1-Regulated Genes across Cell Lines
Have Functional Implications
Because there are a group genes differentially regulated by FOXA1
between MDA-MB-453 and HCC-1954 cell lines (Figure 4, A and B),
we next investigated whether these differences in FOXA1-regulated
genes have any functional implications in molecular apocrine cells.
To assess this, we examined the effect of FOXA1-KD on ERK phos-
phorylation and cell viability using Western blot analysis and MTT
assay, respectively.
In MDA-MB-453 cell line, FOXA1-KD reduced the level of ERK
phosphorylation by 45% compared with the control without any
change in total ERK level (Figure 5A). Moreover, this effect was
associated with a significant decrease in cell viability by approximately
25% (P < .03; Figure 5B). It is notable that ErbB2 level did not
change after FOXA1-KD, indicating that ErbB2 expression is not
regulated by FOXA1 in this cell line (Figure 5A). In contrast,
FOXA1-KD did not affect the level of ERK phosphorylation and cell
viability in HCC-1954 cell line (Figure 5, C and D). These findings
suggest that FOXA1 expression is necessary for maintaining ERK
phosphorylation and cell viability in MDA-MB-453 line as opposed
to HCC-1954 line. Therefore, the functional effects of FOXA1 can
vary across molecular apocrine cells.
RELB and PAK1 Are FOXA1 Target Genes
in ErbB2 Signaling
We subsequently assessed whether selective signature genes are direct
targets of FOXA1. For this purpose, we examined FOXA1 binding to
the promoters of RELB and PAK1, which were the most upregulated
and downregulated genes in the gene signature, respectively
(Figure 3C). It is notable that examination of 1-kb promoter regions
of RELB and PAK1 identified several putative binding sites for FOXA1
(Figure 6A).
To assess FOXA1 binding to the promoters of RELB and PAK1, we
carried out ChIP assays using FOXA1 antibody in MDA-MB-453
cell line. Two sets of primers in proximity to the predicted binding
sites were used for each of the RELB and PAK1 promoters to assess the
end point RT-PCR amplification (Figure 6A). Amplification of input
chromatin at a dilution of 1:50 and ChIP using nonspecific antibody
(rabbit IgG) were applied as positive and negative controls, respec-
tively. Copy number changes were calculated as −Log2 value for each
experimental set (Figure 6, B and C ). ChIP assays demonstrated
significant binding of FOXA1 to the promoters of RELB and PAK1
(P < .01; Figure 6, B and C ). Moreover, the results were reproducible
using both primer sets for each of the promoters (Figure 6, B and C ).
These findings indicate that RELB and PAK1 are FOXA1 target genes
in the ErbB2 signaling pathway.
FOXA1 Binding Partner Corepressor TLE3 Regulates RELB
Our results indicate that FOXA1 negatively regulates a group of
genes in the ErbB2 signaling pathway such as RELB. It has been
shown that FOXA1 can act as a pioneer factor to recruit transcrip-
tional corepressor TLE3 resulting in gene repression distal to the
recruitment site [47,48]. To investigate whether this recruitment of
TLE3 would provide a possible mechanism for the negative regulatory
effects of FOXA1 observed in our study, we examined the role of
TLE3 in the regulation of RELB as an example of a target gene re-
pressed by FOXA1.
We first investigated the effect of TLE3-KD on RELB expression in
MDA-MB-453 cell line. TLE3-KD was carried out using two sets of
siRNA duplexes and the efficiency of KD experiments were assessed
using RT-PCR. We observed approximately 80% reduction in the
level of TLE3 expression with both siRNA duplexes (Figure 6D).
We next measured RELB expression levels after TLE3-KD using
RT-PCR. Notably, there was a significant increase in RELB expres-
sion by 8- to 11-fold after TLE3-KD that was reproducible with both
sets of TLE3-siRNA duplexes (P < .01; Figure 6E ).
We subsequently tested whether TLE3 can be recruited to the RELB
promoter regions that bind FOXA1 using ChIP assays with the same
primer sets applied for FOXA1-RELB ChIP experiments. Amplifi-
cation of input chromatin at a dilution of 1:50 and ChIP using non-
specific antibody (rabbit IgG) were applied as positive and negative
controls, respectively. Copy number changes were calculated as
−Log2 value for each experimental set (Figure 6F). Importantly, we ob-
served significant enrichment for RELB promoter region using TLE3
antibody with both primer sets (P < .01; Figure 6F ). These results
indicate that, in a similar fashion to FOXA1, TLE3 negatively regulates
RELB and is recruited to the same promoter regions of this gene.
Discussion
Molecular apocrine is a subtype of breast cancer that is characterized
by the overexpression of steroid-response genes such as AR and
FOXA1 [2–4]. A key feature of this subtype is a high prevalence of
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Figure 3. FOXA1-regulated gene signature in ErbB2 signaling. (A) Western blot analysis to show FOXA1 protein level after FOXA1-KD
(FOX-KD) in MDA-MB-453 and HCC-1954 cell lines. Fold changes (RR) in band densities were measured relative to the control (CTL).
(B) RT-PCR to demonstrate FOXA1-KD efficiencies in MDA-MB-453 and HCC-1954 cell lines. FOXA1 expression after KD was assessed
relative to nontargeting siRNA control (CTL), and fold change is shown for each cell line and replicate experiment. Rep1 indicates rep-
licate 1; Rep2, replicate 2. (C) Heat map of FOXA1-regulated gene signature in ErbB2 signaling generated using RT-PCR data. Heat map
is constituted of genes with more than two-fold change in expression after FOXA1-KD (KD) in both MDA-MB-453 and HCC-1954 cell
lines. Mean fold change in expression is shown for each gene. Red and green depict up-regulation and down-regulation, respectively.
Bar indicates the range of fold changes in gene expression.
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ErbB2 overexpression, which is present in more than 50% of cases
[2,3,5]. In fact, ErbB2 has a significant biologic role in molecular
apocrine subtype, including a cross talk with the AR signaling path-
way that regulates cell growth and survival [8–10]. FOXA1 is another
notable gene in molecular apocrine signature that has recently gained
much attention with respect to its role as a modulator of steroid re-
ceptors [14–18]. However, there are limited data available regarding
the functional role and regulation of FOXA1 in ER− breast cancer.
In this study, we demonstrated that there is a strong association
between the overexpression of FOXA1 and ErbB2 at both protein
and transcription levels in ER− breast tumors (Figure 1). These find-
ings are further supported by expression microarray studies that have
shown FOXA1 expression is present in most ErbB2+ breast tumors
and cell lines [22,49]. In addition, we observed that FOXA1 expres-
sion is induced by heregulin [8] and reduced by MEK inhibition
in molecular apocrine cells (Figure 2, A and B). Altogether, these
data suggest a role for ErbB2 signaling in the regulation of FOXA1
transcription. Therefore, we sought to identify an interaction between
FOXA1 and ErbB2 signaling in ER− breast cancer.
Our findings suggest that ErbB2 signaling regulation of FOXA1 is
mediated through transcription factors CREB1 and c-Fos (Figure 2,
D-F ). CREB1 is a critical downstream mediator of the EGFR-ErbB2
pathway, which is activated by both Akt and ERK signaling [42–
44,50]. It is notable that we have previously identified AR as another
CREB1 target gene [9]. Moreover, CREB1 strongly activates both
FOXA1 and AR promoters by more than 10-fold (Figure 2D and
Chia et al. [9]). These findings suggest that CREB1 acts as a key tran-
scription factor in the regulation of steroid-response genes. C-Fos is
the second transcription factor in the ErbB2 signaling that activates
FOXA1. C-Fos is a part of AP1 family of transcription factors that is
activated by ERK-mediated phosphorylation and increase in mRNA
expression [46,51]. Interestingly, c-Fos is also one of the upregulated
genes following FOXA1-KD, suggesting that c-Fos expression itself is
negatively regulated by FOXA1 (Figure 3C ).
Figure 4. ErbB2 signaling genes that are differentially regulated by FOXA1 between molecular cell lines. (A) RT-PCR to demonstrate the
relative folds of gene expression to control after FOXA1-KD in MDA-MB-453 cell line. Box plots show genes with more than two-fold
change in expression after FOXA1-KD, which were unique to MDA-MB-453 cell line. (B) RT-PCR to demonstrate the relative folds of gene
expression to control after FOXA1-KD in HCC-1954 cell line. Box plots to show genes with more than two-fold change in expression after
FOXA1-KD, which were unique to HCC-1954 cell line.
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Another underlying mechanism that explains the association be-
tween FOXA1 and ErbB2 overexpression is the role of transcription
factor AP2α in regulating both of these genes. AP2α is an established
transcriptional regulator of ErbB2 that contributes to the overexpres-
sion of this gene in breast tumors [35–40]. In addition, we have dem-
onstrated that FOXA1 is an AP2α target gene, and there is a significant
correlation between the expression patterns of these two genes in a
cohort of 30 ER− cell lines (Figures 2, D-F , and 1F ). The expression
data used for this correlation analysis was derived from the largest geno-
mics data set available for ER-negative cell lines [33]. It is notable that
AP2α itself is a member of steroid-response signature [3], suggesting
that a network of interacting transcription factors including AR,
FOXA1, and AP2α plays a significant role in the biology of molecular
apocrine breast cancer. Altogether, we have identified two layers of
transcriptional regulation to explain the association between FOXA1
and ErbB2 overexpression in molecular apocrine cells. In one layer,
ErbB2 signaling genes CREB1 and c-Fos regulate FOXA1 transcription
and in another layer, AP2α regulates the expression of both FOXA1 and
ErbB2 genes (Figure 7).
Moreover, our data suggest that FOXA1, in turn, regulates the tran-
scription of ErbB2 signaling genes in molecular apocrine cells (Figures 3
and 4). FOXA1-regulated genes include a core gene signature that
is shared across two molecular apocrine cell lines. Importantly,
FOXA1-KD results in both down-regulation and up-regulation of
ErbB2 signaling genes, suggesting that FOXA1 has both positive and
negative transcriptional activities in molecular apocrine cells. Further-
more, the most upregulated (RELB) and downregulated (PAK1) genes
in the signature are direct FOXA1 targets (Figure 6, B and C ). These
findings indicate that FOXA1 acts as a dual-function transcription fac-
tor with both activating and repressive activities (Figure 7). This pattern
of gene regulation is in agreement with a recent study that showed
FOXA1-KD results in a similar number of downregulated and upregu-
lated genes in prostate cancer cells [15]. In fact, the repressive function
of FOXA1 on RELB can be explained by the recruitment of its binding
Figure 5. The effect of FOXA1 KD on ERK phosphorylation and cell viability. (A)Western blot analysis tomeasure the level of phosphorylated
ERK (ph-ERK), total ERK, and ErbB2 after FOXA1-KD (FOX-KD) in MDA-MB-453 cell line. Fold change was assessed relative to nontargeting
siRNA control (CTL). (B) MTT assay to measure cell viability after FOX-KD in MDA-MB-453 cell line. CTL indicates nontargeting siRNA con-
trol. *P < .03 is for FOX-KD versus CTL. (C) Western blot analysis to measure the level of phosphorylated ERK (ph-ERK) and total ERK after
FOX-KD in HCC-1954 cell line. (D) MTT assay to measure cell viability after FOX-KD in HCC-1954 cell line. All error bars, ±2 SEM.
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Figure 6. FOXA1 binding to RELB and PAK1 promoters and TLE3 regulation of RELB. (A) Putative FOXA1 binding sites in 1 kb promoter
regions of RELB and PAK1. P1 (primer set 1) and P2 (primer set 2) are regions of amplification for ChIP assays. (B) ChIP assay for RELB
promoter using FOXA1 antibody in the MDA-MB-453 cell line. The results of end point RT-PCR amplification for ChIP assay are shown
with two sets of primers for RELB promoter. Input indicates input at a dilution of 1:50; Neg. CT, nonspecific antibody. The relative copy
number changes to control are shown as −Log2 values. *P < .01 is for FOXA1 Ab versus Neg. CT. (C) ChIP assay for PAK1 promoter
using FOXA1 antibody. The results of end point RT-PCR amplification for ChIP assay are shown with two sets of primers for PAK1
promoter as described in B. (D) RT-PCR to demonstrate TLE3-KD efficiencies with two sets of siRNA duplexes (KD1 and KD2) in
MDA-MB-453 cell line. TLE3 expression after KD was assessed relative to nontargeting siRNA control (CTL), and the fold change is
shown for each duplex. (E) RT-PCR to show RELB expression levels after TLE3-KD with two sets of siRNA duplexes as described in D.
(F) ChIP assay for RELB promoter using TLE3 antibody. The results of end point RT-PCR amplification for ChIP assay are shown with
two sets of primers for RELB promoter as described in B. *P < .01 is for TLE3 Ab versus Neg. CT. All error bars, ±2 SEM.
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partner corepressor TLE3 (Figure 6, D-F). In this process, FOXA1 re-
cruitment of TLE3 leads to gene repression distal to the recruitment
site [47]. In addition, the removal of FOXA1 as a pioneering factor
by KD can result in transcriptional reprogramming mediated through
other transcription factors [15,19].
It is notable that a group of FOXA1-regulated genes vary across
molecular apocrine cell lines leading to the differences in the func-
tional effects of FOXA1 between these lines (Figures 4 and 5). In
MDA-MB-453 cells, FOXA1 expression is necessary for ERK phos-
phorylation and maintaining cell viability. These effects can be ex-
plained by the fact that most of FOXA1-regulated genes in this
cell line, including key ERK signaling mediators GRB2 and BRAF,
are positively regulated by this gene (Figures 3C and 4A). It is known
that GRB2, which mediates Ras activation, and BRAF, which is a Ras
effector, are both required for full activation of ERK [52,53]. There-
fore, down-regulation of these genes can explain the reduction in ERK
phosphorylation and cell viability after FOXA1-KD in MDA-MB-
453 cells. In contrast, FOXA1 expression is not necessary to maintain
ERK phosphorylation and cell viability in HCC-1954 cell line, and
this corresponds with the fact that FOXA1-KD results in a similar
number of positively and negatively regulated genes in this cell line,
which does not include GRB2 and BRAF (Figures 3C and 4B). These
observations point out to the diversity of FOXA1 functional activities
in molecular apocrine cells.
We identified RELB as a FOXA1 target gene that is markedly re-
pressed by FOXA1 and TLE3 expression in molecular apocrine cells
(Figures 3C and 6). RELB is a member of NF-κB family that can be
activated by the EGFR-ErbB2 signaling pathway [54–56]. In addi-
tion, we observed that FOXA1 regulates another NF-κB–related
gene IKBKB (IκB kinase B) in MDA-MB-453 cells (Figure 4A).
Most widely studied mechanisms for the regulation of NF-κB activ-
ity involve changes in the phosphorylation levels of IκBα and RELA/
p65 proteins [57]. Our results suggest that FOXA1-mediated tran-
scriptional regulation of RELB may provide an alternative mech-
anism for the regulation of NF-κB pathway. It is notable that the
NF-κB family of proteins has a significant role in the biology of
ErbB2+/ER− breast cancer [55]. In addition to being involved in
the ErbB2 signaling, some of the FOXA1-regulated genes such as
RELB and IKBKB are also part of other signaling pathways such as
NF-κB. Therefore, FOXA1 may play a regulatory function in inter-
actions between some of the key signaling pathways such as AR, ErbB2,
and NF-κB in molecular apocrine cells.
Furthermore, PAK1 (p21-activated kinase 1) represents a direct tar-
get of FOXA1 that is positively regulated by this gene (Figures 3C
and 6C ). PAK1 interacts with the GRB2 adapter protein, and this
association is enhanced by the induction of EGFR signaling [58].
Considering that FOXA1 positively regulates GRB2 in one of the
molecular apocrine lines (Figure 4A), this combined regulation of
GRB2 and PAK1 can significantly modulate the downstream ERK
signaling pathway.
In summary, we have identified a cross-regulation network between
FOXA1 and the ErbB2 signaling pathway (Figure 7). Importantly, this
cross-regulation connects FOXA1 to some of the key signaling ele-
ments in ER− breast cancer such as ERK-CREB1 axis, NF-κB genes,
and transcription factor AP2α. Therefore, this novel signaling network
has a critical function in the biology of ER− breast cancer and may pro-
vide a potential therapeutic target in this disease.
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Figure W1. Percentage of FOXA1 positive with immunohisto-
chemistry score (S ) > 24 in ErbB2+/ER− and ErbB2−/ER−
breast tumors. *P< .01 is for ErbB2+ versus ErbB2− groups. Bars,
±2 SEM.
Table W1. Expression of FOXA1, AP2α, and ErbB2 in ER-negative Breast Cancer Cell Lines
Extracted from the Microarray Data Published by Neve et al. [33].
Cell Line Gene
FOXA1 AP2α ErbB2 NFOXA1 NAP2α NErbB2
AU565 7.82 7.76 5.90 1.33 0.94 1.46
BT20 6.69 8.52 3.99 1.14 1.03 0.99
BT549 4.75 8.03 3.92 0.81 0.97 0.97
HBL100 5.22 7.79 3.58 0.89 0.94 0.89
HCC38 5.89 7.37 3.79 1.01 0.89 0.94
HCC70 5.77 8.15 4.16 0.98 0.98 1.03
HCC202 8.71 8.03 8.05 1.49 0.97 1.99
HCC1143 5.22 7.40 4.22 0.89 0.89 1.04
HCC1187 5.83 8.75 3.87 0.99 1.06 0.96
HCC1500 5.99 8.46 3.74 1.02 1.02 0.93
HCC1569 5.08 5.84 7.64 0.87 0.71 1.89
HCC1937 6.64 8.43 4.05 1.13 1.02 1
HCC1954 7.53 8.26 7.58 1.28 1 1.88
HCC2157 5.36 8.66 4.43 0.91 1.05 1.1
HCC2185 8.94 8.96 4.81 1.52 1.08 1.19
HCC3153 7.08 9.20 4.95 1.21 1.11 1.23
HS578T 5.72 8.02 4.03 0.98 0.97 1
MDAMB157 4.70 6.95 3.95 0.8 0.84 0.98
MDAMB231 5.48 4.87 3.37 0.94 0.59 0.84
MDAMB435 5.52 8.29 3.79 0.94 1 0.94
MDAMB436 5.09 5.06 3.73 0.87 0.61 0.92
MDAMB453 9.35 9.25 4.41 1.59 1.12 1.09
MDAMB468 6.80 9.06 3.41 1.16 1.09 0.85
SKBR3 8.12 8.62 5.61 1.38 1.04 1.39
SUM149PT 5.78 8.56 4.13 0.99 1.03 1.02
SUM159PT 5.63 5.94 3.76 0.96 0.72 0.93
SUM185PE 8.79 9.85 4.00 1.5 1.19 0.99
SUM190PT 7.64 9.36 7.56 1.3 1.13 1.87
SUM225CWN 9.55 9.15 10.34 1.63 1.1 2.56
SUM1315 5.23 7.11 4.00 0.89 0.86 0.99
N indicates normalized data to the median expression of each gene across the cohort of ER-
negative cell lines.
